Exocrine Pancreatic Insufficiency(EPI) Therapeutics Market – Regional Analysis
Geographically, the global ExocrinePancreatic Insufficiency (EPI) Therapeutics Market is segmented into NorthAmerica, Latin America, Europe, Middle East, Asia Pacific, and Africa. NorthAmerica is expected to dominate the global exocrine pancreatic insufficiency(EPI) therapeutics market due to increasing incidence and prevalence cases ofthese conditions occurring in this region. EPI is mostly characterized with itsassociated conditions such as cystic fibrosis, pancreatic cancer, chronicpancreatitis, gastrointestinal surgery, and others.
Exocrine pancreatic insufficiency(EPI) is a condition associated with deficiency of exocrine pancreatic enzymesthat results in the inability to digest food or maldigestion. EPI may beassociated with certain diseases and conditions that affect the pancreas suchas cystic fibrosis, chronic pancreatitis, Shwachman–Diamond syndrome, andothers. Chronic pancreatitis (CP) is the most common cause of EPI in adultsthat is followed by cystic fibrosis (CF). CF is an inherited genetic conditionthat leads to chronic disease, which affects lungs, digestive, and reproductivesystem. Patients suffering from exocrine pancreatic insufficiency cannotproperly digest proteins, fats, and carbohydrates in the food that results inpoor absorption of nutrients in the body.
Furthermore, EPI is associatedwith uncomfortable gastrointestinal (GI) symptoms such as bloating, gas, andoily diarrhea that floats and is difficult to flush. The symptoms of EPI may besimilar to other gastrointestinal disorders such as Crohn’s disease, celiacdisease, irritable bowel syndrome (IBS), ulcerative colitis, and smallintestinal bacterial overgrowth (SIBO), which makes EPI difficult to diagnose. However, there arethree major tests used for diagnosis of EPI that include, fecal elastase test,fecal fat test, and direct pancreatic function test.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2020
Exocrine Pancreatic Insufficiency(EPI) Therapeutics Market – Drivers
Exocrine pancreatic insufficiencyis associated with certain diseases and conditions such as chronicpancreatitis, cystic fibrosis, pancreatectomy, pancreatic cancer,gastrointestinal surgery, type I and type III C diabetes, and other conditionsincluding autoimmune pancreatitis, celiac disease, and inflammatory boweldisease. Moreover, high prevalence of these conditions leads to EPI, which inturn fuels growth of exocrine pancreatic insufficiency (EPI) therapeuticsmarket. For instance, according to a report by the Cystic Fibrosis Foundation,2010, around 1,000 new cases of cystic fibrosis are diagnosed globally every year.
Furthermore, according to areport by the American Lung Association, 2010, cystic fibrosis is the secondmost inherited disorder in infants in the U.S. The report further stated thataround 10 million cases in the U.S are symptomless carriers of the defectivecystic fibrosis gene and around 3,708 deaths were reported due to cysticfibrosis between 1999 and 2006. Moreover, pancreatic cancer is a major factorthat leads to EPI. According to CancerResearch UK 2015, around 9,800 new pancreatic cancer cases were registered inthe U.K. annually, from 2013 to 2015. The report further stated that pancreaticcancer is the 11th most common cancer in the U.K. that accounted for 3% of allnew cancer cases, in 2015.
According to the American CancerSociety (ACS), in the U.S 2018, around 55, 440 people are expected to bediagnosed with pancreatic cancer, and around 44,330 people are expected tosuccumb to pancreatic cancer. Furthermore, according to the National CancerInstitute, from 2011 to 2015, 12.6 per 100,000 new cases of pancreatic cancerwere registered, annually, in the U.S.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/exocrine-pancreatic-insufficiency-epi-therapeutics-market-2020
According to a report by theDiabetes.co.uk, 2018, EPI was more evident in the people with insulin-dependentdiabetes. According to the same source, in 2003, a study conducted on around1,000 diabetic patients found that insulin-dependent diabetes was more likelyto produce abnormally low levels of exocrine pancreatic enzymes. Furthermore,between 25% and 50% of insulin-dependent diabetes patients were found to havedeveloped exocrine pancreatic insufficiency. Moreover, high prevalence ofdiabetes may increase the risk of EPI. For instance, according to InternationalDiabetes Federation (IDF) Diabetes Atlas: 2017, number of people with diabetes,worldwide, aged between 20 to 79 years in 2017 was around US$ 425 million, and the number is estimatedto increase to 48% in 2045, accounting for around US$ 629 million.
Exocrine Pancreatic Insufficiency(EPI) Therapeutics Market – Competitive Analysis
Key players operating in theexocrine pancreatic insufficiency (EPI) therapeutics market include, AbbVie,Inc., Digestive Care, Inc., Janssen Pharmaceuticals, Inc., AntheraPharmaceuticals, Inc., Allergan plc, AzurRx BioPharma, Inc., and others. Keyplayers operating in this market are focused on product regulatory approvalsand acquisition strategies to enhance their share in the market. For instance,in May 2013, AbbVie, Inc. announced the availability of CREON (pancrelipase)36,000 Lipase-unit Capsules for patients with EPI in the U.S. Furthermore, inMay 2018, VIVUS, Inc. entered into definitive agreement with JanssenPharmaceuticals, Inc. to acquire all the product rights for PANCREAZE(pancrelipase) delayed-release capsules in the U.S. and Canada.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2020
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
